Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components

A variety of Good Manufacturing Practice (GMP) compliant processes have been reported for production of non-replicating adenovirus vectors, but important challenges remain. Most clinical development of adenovirus vectors now uses simian adenoviruses or rare human serotypes, whereas reported manufact...

Descripción completa

Detalles Bibliográficos
Autores principales: Fedosyuk, Sofiya, Merritt, Thomas, Peralta-Alvarez, Marco Polo, Morris, Susan J, Lam, Ada, Laroudie, Nicolas, Kangokar, Anilkumar, Wright, Daniel, Warimwe, George M, Angell-Manning, Phillip, Ritchie, Adam J, Gilbert, Sarah C, Xenopoulos, Alex, Boumlic, Anissa, Douglas, Alexander D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949866/
https://www.ncbi.nlm.nih.gov/pubmed/31047679
http://dx.doi.org/10.1016/j.vaccine.2019.04.056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949866/
https://www.ncbi.nlm.nih.gov/pubmed/31047679
http://dx.doi.org/10.1016/j.vaccine.2019.04.056

Ejemplares similares